Comparative Effects of Emerging Lp(a)‐Lowering Agents and PCSK9‐Directed Therapies on Lipoprotein(a): A Network Meta‐Analysis of Randomised Clinical Trials
Jihad Abu Zayed, Nada A Al‐Awamleh, Mahmoud Hamad, Mohammad Ibrahim Mahmoud Hdaib, Hazem Ayesh · 2026
Read Comparative Effects of Emerging Lp(a)‐Lowering Agents and PCSK9‐Directed Therapies on Lipoprotein(a): A Network Meta‐Analysis of Randomised Clinical Trials by Jihad Abu Zayed, Nada A Al‐Awamleh, Mahmoud Hamad, Mohammad Ibrahim Mahmoud Hdaib, Hazem Ayesh (2026) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-13341347.txt.
Description
Jihad Abu Zayed and colleagues weighed lipoprotein(a) drugs in 2026 by pooling randomised trials. High lipoprotein(a) is a gene linked heart risk factor that often stays high despite strong LDL cholesterol lowering. The team searched PubMed, Embase, Web of Science, and Cochrane CENTRAL through 6 December 2025 for trials in adults with at least eight weeks follow up that report lipoprotein(a).
New drugs, with siRNAs, antisense drugs, and an oral assembly blocker, were weighed against PCSK9 directed drugs. Outcomes were placebo adjusted percent change in lipoprotein(a), LDL cholesterol, other lipids, and safety. The synthesis helps doctors judge which lipoprotein(a) route lowers the marker most safely while outcome trials mature.
Catalog record
| CREATOR | Jihad Abu Zayed, Nada A Al‐Awamleh, Mahmoud Hamad, Mohammad Ibrahim Mahmoud Hdaib, Hazem Ayesh |
|---|---|
| YEAR | 2026 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 36 KB |
| VERSION | 1.0 |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |